TBPMF - Tetra Bio reports clinical advancements and establishment of ATM equity program

Tetra Bio-Pharma (TBPMF) announces clinical advancements in REBORN1 trial; ARDS-003 trial and update on capital raise. The REBORN1 trial is designed to evaluate the effect of QIXLEEF, against immediate release oral morphine sulfate on onset of pain relief in people living with cancer.The first patient has entered the clinical trial and over the next months, outcome of the cannabis treatment versus immediate-release morphine will be provided. Tetra also announces results of first study in Sars-CoV-2 infected mice. Pre-clinical studies are ongoing to examine ARDS-003 in Sars-CoV-2 infected mice (hACE2) to generate initial data on the dosing and efficacy. Daily Health Scores ((DHS)) were assessed in ACE2 mice treated with vehicle (no drug) or ARDS-003 at Day 7 post infection/treatment compared to sham animals (no infection, no treatment). Higher scores are indicative of poor clinical prognosis.Infected animals dosed with ARDS-003 (10 mg/kg) resulted in lower DHS scores at 7 days compared to no-treatment

For further details see:

Tetra Bio reports clinical advancements and establishment of ATM equity program